mycosis fungoides

(redirected from Cutaneous T-cell Lymphoma)
Also found in: Dictionary, Thesaurus, Medical.
Related to Cutaneous T-cell Lymphoma: mycosis fungoides, Sezary syndrome

mycosis fungoides

[mī¦kōs·əs fəŋ′gȯi‚dēz]
(medicine)
A lymphoma of the skin, usually present in several sites when first diagnosed, that may remain confined to the skin for 10 or more years before eventually spreading to internal organs and causing death.
Mentioned in ?
References in periodicals archive ?
cutaneous T-cell lymphomas and identified 5 cases of primary cutaneous acral [CD8.
Finally, severe psoriasis was linked to a more than ninefold increase in risk of cutaneous T-cell lymphoma (aHR, 9.
The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects
Primary cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of lymphomas that maybe present in the skin without any evidence of extracutaneous disease at the time of diagnosis [1, 2].
Phase 2 and 3 clinical trial of oral bexarotene for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
For example, the company is testing drugs for cutaneous T-cell lymphoma and peripheral T-cell lymphoma, both of which are types of non-Hodgkin's lymphoma.
The randomized, double-blind, controlled clinical study is the largest ever undertaken involving patients with cutaneous T-cell lymphoma.
Recombinant human interleukin-12 induces lesion regression in some cutaneous T-cell lymphomas, reported Dr.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), San Diego, has submitted a regulatory application to market its anti-cancer medicine ONZAR(TM) (denileukin diftitox) in the European Union for the treatment of cutaneous T-cell lymphoma (CTCL) patients.
A gel formulation of 1% bexarotene has been approved for treating cutaneous lesions in patients with early-stage cutaneous T-cell lymphoma who have refractory disease or persistent disease after being treated with other therapies or who have not tolerated other therapies.
More recent results suggest surface DNA may play a destructive role in autoimmune diseases and a useful role in drug treatment for psoriasis and a cancer called cutaneous T-cell lymphoma.